CIS Pharma develops novel antibody-drug- conjugates (ADCs) based on our proprietary polymer carrier platform. Our polymers serve as carriers that are loaded with cytotoxic drugs, radioisotopes or other active entities. The carrier together with its cargo is conjugated to a target-specific antibody using site-directed linker chemistry, different from the linker chemistry used to attach the payload. As a result, our polymer drug conjugates (PDC) offer a higher number of binding sites compared to conventional ADCs.
ADC’s combine target-specificity of an antibody to a tumor antigen with a potent cytotoxic drug. In comparison to the administration of a cytotoxic drug alone, side effects are significantly reduced as normal cells remain unimpaired during treatment. Conventional ADCs use linkers to load cytotoxic drugs onto the antibody directly, limiting the number of drug cargo that is delivered to the tumor cells.
CIS Pharma’s PDCs and applied linker chemistry are designed to be resistant to degradation, thereby offering higher plasma stability and shelf life in comparison to other ADCs. After drug release, the degradation products of our conjugates are eliminated by renal excretion. In cell toxicity studies, both monomers as well as polymers show excellent toxicity profiles.
Our carriers will increase the solubility of hydrophobic drugs that suffer from low bioavailability and are expected to extend half-life of conjugates. They allow conjugation of different classes of cytotoxic drugs and combinations thereof. Our ADC platform also include binding sites for radioisotopes. Our conjugation technology is compatible with an array of target-specific agents such as antibodies, antibody fragments, aptamers and smaller homing agents.